Clinical trials: Female Genital Disease
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06128551
- Testing
- Elironrasib, Daraxonrasib
- Where
- 56 sites in United States, France and 5 more
- Volunteers
- 534 people
- Sponsor
- Revolution Medicines, Inc.
Ovarian Cancer
Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy
The purpose of this study is to determine whether the investigational drug catumaxomab delivered in the planned treatment schedule is a safe and effective treatment for women with advanced ovarian cancer who experience a complete…
- Trial name
- NCT00377429
- Testing
- catumaxomab
- Where
- 12 sites in United States
- Volunteers
- 47 people
- Sponsor
- Neovii Biotech
Endometriosis, Omics
SH-SDU Shandong Endometriosis Reproductive Cohort
Endometriosis (EMs) is a chronic, estrogen-dependent, multi-systemic disease that affects approximately 190 million women worldwide.
- Conditions
- Endometriosis, Omics, Assisted Reproductive Technology
- Trial name
- NCT07558629
- Where
- China
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- The Second Hospital of Shandong University
Vulvodynia
High-level Laser for Provoked Vestibulodynia
This is a randomized feasibility and acceptability study investigating the effects of laser treatment in women suffering from provoked vestibulodynia compared to a sham-laser treatment.
- Trial name
- NCT04502810
- Testing
- High-level laser therapy
- Where
- Canada
- Volunteers
- 41 people
- Sponsor
- Université de Sherbrooke
Cervical Cancer
Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer
This study is an open-label, multi-center Phase II clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate and platinum-based chemotherapy in the treatment of recurrent/metastatic…
- Trial name
- NCT07627620
- Testing
- Camrelizumab, Famitinib Malate, Chemotherapy
- Volunteers
- 54 people
- Sponsor
- Hunan Cancer Hospital
Ovarian Cancer
Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors
This is a single site, open label, Phase 1 study using a 3 + 3 dose escalation design in two cohorts of adults with recurrent, platinum-resistant ovarian tumors.
- Trial name
- NCT06646627
- Testing
- B7-H3CART
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Stanford University
Ovary Cancer
The Efficacy and Safety of FRD001 in Ultrasound Contrast Imaging for Malignant Ovarian Masses in Women
This is a Prospective, Self-Controlled, Open-Label, Multicenter Clinical Trial. The purpose of this study is to demonstrate the efficacy and safety of FRD001 injection in ultrasound contrast imaging for the differentiation…
- Trial name
- NCT06556342
- Testing
- FRD001
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Tongji Hospital
Vulvar Lichen Sclerosus
A Study to Evaluate Platelet Rich Plasma to Treat Vulvar Lichen Sclerosus
The purposes of this study are to determine the safety and feasibility of autologous platelet-rich plasma for the treatment of vulvar lichen sclerosus, and to determine the efficacy of autologous platelet-rich plasma for the…
- Trial name
- NCT04967170
- Testing
- Autologous Platelet-Rich Plasma (PRP)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jennifer R. Arthurs
Atrophy, Vaginal Atrophy
Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects
The purpose of this study is to assess the use of the Alma CO2 Pixel FemiLift™ in the treatment of VulvoVaginal Atrophy (VVA) in postmenopausal female subjects.
- Conditions
- Atrophy, Vaginal Atrophy, Genital Diseases, Female
- Trial name
- NCT02747641
- Testing
- Pixel CO2 Laser System
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Alma Lasers Inc.
Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
This phase II trial is studying how well oxaliplatin works in treating young patients with recurrent solid tumors that have not responded to previous treatment.
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Hepatoblastoma, Childhood Hepatocellular Carcinoma
- Trial name
- NCT00091182
- Testing
- oxaliplatin
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- National Cancer Institute (NCI)
Gynecologic Neoplasms
A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer
This is a Phase Ib, open-label, non-randomized study in patients with previously treated advanced ovarian or endometrial cancer (Part 1) and platinum-sensitive ovarian cancer or triple-negative breast cancer (TNBC) (Part 2) to…
- Trial name
- NCT03101280
- Testing
- Atezolizumab, Rucaparib
- Where
- 11 sites in Australia, France and 2 more
- Volunteers
- 29 people
- Sponsor
- Hoffmann-La Roche
Endometrial Adenocarcinoma
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.
- Trial name
- NCT05548296
- Testing
- ACR-368, Gemcitabine, OncoSignature
- Where
- 90 sites in United States, France and 3 more
- Volunteers
- 350 people
- Sponsor
- Acrivon Therapeutics
Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor
Collecting Tumor Samples From Patients With Gynecological Tumors
This laboratory study is collecting tumor tissue and blood samples from patients with gynecologic tumors. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help in…
- Conditions
- Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
- Trial name
- NCT00897442
- Testing
- Laboratory Biomarker Analysis
- Where
- 187 sites in United States
- Volunteers
- 275 people
- Sponsor
- Gynecologic Oncology Group
Cervix Cancer, Uterine Cancer
Prolonged Grief and Perception of Femininity in Gynecological Cancer Patients
The aim of this study is to determine the effect of the 'Feminine Identity Improvement Program', based on cognitive behavioral and expressive techniques applied to gynecological cancer patients, on prolonged grief reactions and…
- Conditions
- Cervix Cancer, Uterine Cancer, Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT05529303
- Testing
- Such as art therapy, play therapy, breathing techniques
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Kevser Pamuk
Atrophic Vaginitis
A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis
The purpose of this study is to determine the therapeutic equivalence of Mylan's estradiol vaginal cream to Estrace® cream and superiority of both products to placebo.
- Trial name
- NCT02195986
- Testing
- Estradiol Vaginal Cream, 0.01%, Estrace® 0.01% cream
- Where
- 21 sites in United States
- Volunteers
- 366 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Infertility, Female
Live Birth After Additional Tubal Flushing With Oil-based Contrast Versus no Additional Flushing:
Ten to 15 percent of couples in their reproductive lifetime face fertility problems which is defined by WHO as the absence of pregnancy after minimal 12 months of unprotected sexual intercourse.
- Trial name
- HYFOIL (NCT04379973)
- Testing
- Lipiodol Ultra Fluide®
- Where
- 16 sites in Belgium
- Volunteers
- 736 people
- Sponsor
- Dafne Balemans
Cancer
Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation
RATIONALE: White blood cells from donors who have been exposed to cytomegalovirus may be able to help prevent this infection from occurring in patients who are undergoing bone marrow or peripheral stem cell transplantation.
- Trial name
- NCT00002673
- Testing
- infection prophylaxis and management
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Benign Prostate Hyperplasia, Bladder Outlet Obstruction
En-bloc With Early Apical Release Versus Lobe-by-lobe LASER Enucleation of the Prostate
Since its introduction in 1998 , and through numerous level 1a evidence, Holmium Laser enucleation of the prostate (HoLEP) has come to be considered a size-independent golden standard treatment for management of bladder outlet…
- Trial name
- NCT07014969
- Testing
- En-bloc HoLEP
- Where
- Egypt
- Volunteers
- 123 people
- Sponsor
- Mansoura University
Endometrioma
Endometrioma Sclerotherapy and Ovarian Preservation
A randomised controlled trial assessing ovarian reserve after laparoscopic ethanol sclerotherapy of ovarian endometrioma compared to standard treatment of surgical excision of endometrioma.
- Trial name
- ENDOSAVE (NCT06775769)
- Testing
- Sclerotherapy, Routine Care
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer, HER2-Negative Breast Cancer
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
This clinical trial is studying the drug Ribociclib (LEE011) in combination with an immunotherapy drug called PDR001 (a therapy that uses the body's own immune system to control cancer) as a possible treatment for metastatic…
- Conditions
- Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer, HER2-Negative Breast Cancer, Metastatic Epithelial Ovarian Cancer
- Trial name
- NCT03294694
- Testing
- Ribociclib, PDR001, Fulvestrant
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Dana-Farber Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.